{"id":2626,"date":"2018-05-03T23:22:19","date_gmt":"2018-05-03T17:52:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2626"},"modified":"2023-02-10T11:14:06","modified_gmt":"2023-02-10T05:44:06","slug":"business-cocktail-latest-pharma-news-5","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-5","title":{"rendered":"Horizon Discovery declines Abcam\u2019s USD 367 million takeover bid"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Horizon Discovery declines Abcam\u2019s USD 367 million takeover bid<\/strong><\/p>\n<p style=\"text-align: justify;\">Horizon Discovery has&nbsp;recently rejected&nbsp;a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique and has issued a strong rejection to the offer of Abcam. Horizon\u2019s board believes that the bid undervalues the company due to which it has rejected the offer.<\/p>\n<p style=\"text-align: justify;\"><strong>Casma Therapeutics kick starts with USD 58.5 million for treatments targeting the cell&#8217;s garbage disposal<\/strong><\/p>\n<p style=\"text-align: justify;\">Casma Therapeutics is heading with a USD 58.5 million series a funding to aim at a range of&nbsp;conditions&nbsp;through a process called cell garbage disposal. Funding was backed by Third Rock, this platform that could possibly lay the foundation for disease-modifying therapies for several neurodegenerative and inflammatory diseases.<\/p>\n<p style=\"text-align: justify;\"><strong>Refuge Biotech successfully bagged USD 25 million from Chinese funding firms for &#8216;intelligent&#8217; CAR-T<\/strong><\/p>\n<p style=\"text-align: justify;\">Sequioa China and 3SBio&nbsp;led USD 25 million series B funding for&nbsp;Refuge Biotech. The funding will fuel the company\u2019s dead Cas9-based cell therapies. The therapy uses mutated Cas9 enzymes to control the expression of certain genes, resulting in therapeutic cells that are programmed to make cancer-fighting decisions inside the body.<\/p>\n<p style=\"text-align: justify;\"><strong>Johnson &amp; Johnson signed USD 140 million deal for preclinical stage oncolytic virus startup<\/strong><\/p>\n<p style=\"text-align: justify;\">Johnson &amp; Johnson is&nbsp;paying&nbsp;USD 140 million for buyout of oncolytic immunotherapy startup BeneVir Biopharm. The deal gives J&amp;J control of preclinical candidates designed to avoid the body\u2019s immune system, enabling them to kill cancer cells for longer period of time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Horizon Discovery declines Abcam\u2019s USD 367 million takeover bid Horizon Discovery has&nbsp;recently rejected&nbsp;a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique and has issued a strong rejection to the offer of Abcam. Horizon\u2019s board believes that the bid undervalues the company due to which it has [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17621,776,17619,1155,920,341,1029,1230,1261,639,1610,17620],"industry":[17225],"therapeutic_areas":[17235,17245,17228],"class_list":["post-2626","post","type-post","status-publish","format-standard","hentry","category-notizia","tag-benevir-biopharm","tag-business-cocktail","tag-casma-therapeutics","tag-consultancy","tag-horizon-discovery","tag-johnson-johnson","tag-market-report","tag-pharma-consultancy","tag-pharma-consulting","tag-pharma-news","tag-pharmaceutical-industry-news","tag-refuge-biotech","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News and Updates | Casma Therapeutics, J&amp;J, Refuge<\/title>\n<meta name=\"description\" content=\"Horizon Discovery has\u00a0recently rejected\u00a0a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-5\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News and Updates | Casma Therapeutics, J&amp;J, Refuge\" \/>\n<meta property=\"og:description\" content=\"Horizon Discovery has\u00a0recently rejected\u00a0a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-5\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-03T17:52:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T05:44:06+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News and Updates | Casma Therapeutics, J&J, Refuge","description":"Horizon Discovery has\u00a0recently rejected\u00a0a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-5","og_locale":"en_US","og_type":"article","og_title":"Pharma News and Updates | Casma Therapeutics, J&J, Refuge","og_description":"Horizon Discovery has\u00a0recently rejected\u00a0a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique.","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-5","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-05-03T17:52:19+00:00","article_modified_time":"2023-02-10T05:44:06+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-5","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-5","name":"Pharma News and Updates | Casma Therapeutics, J&J, Refuge","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2018-05-03T17:52:19+00:00","dateModified":"2023-02-10T05:44:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Horizon Discovery has\u00a0recently rejected\u00a0a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-5"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BeneVir Biopharm<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Cocktail<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Casma Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Horizon Discovery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson &amp; Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">market report<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical industry news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Refuge Biotech<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BeneVir Biopharm<\/span>","<span class=\"advgb-post-tax-term\">Business Cocktail<\/span>","<span class=\"advgb-post-tax-term\">Casma Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">Horizon Discovery<\/span>","<span class=\"advgb-post-tax-term\">Johnson &amp; Johnson<\/span>","<span class=\"advgb-post-tax-term\">market report<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical industry news<\/span>","<span class=\"advgb-post-tax-term\">Refuge Biotech<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on May 3, 2018","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on May 3, 2018 11:22 pm","modified":"Updated on Feb 10, 2023 11:14 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2626"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2626\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2626"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2626"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}